Cover Image
市場調查報告書

肌肉萎縮症 : 開發平台分析

Muscle Atrophy - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 269897
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
肌肉萎縮症 : 開發平台分析 Muscle Atrophy - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 41 Pages
簡介

肌肉萎縮症是由於肌肉細胞衰弱和受損而發病。久坐的生活型態加上不運動,或是運動量過低是這個疾病最常見的原因。

本報告提供肌肉萎縮症治療藥的開發情形的相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肌肉萎縮症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肌肉萎縮症:企業開發中的治療藥

肌肉萎縮症:大學/機關研究中的治療藥

肌肉萎縮症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肌肉萎縮症:企業開發中的產品

肌肉萎縮症:大學/機關研究中的產品

肌肉萎縮症的治療藥開發企業

  • Biogen, Inc.
  • Eli Lilly and Company
  • Fate Therapeutics, Inc.
  • Rigel Pharmaceuticals, Inc.

肌肉萎縮症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACE-083
  • Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders
  • BIIB-023
  • landogrozumab
  • Small Molecule for Muscular Dystrophy and Other Muscle Disorders
  • Small Molecule to Inhibit Growth and Differentiation Factor 8 for Ventilator Atrophy

肌肉萎縮症:最近的開發平台趨勢

肌肉萎縮症:暫停中的計劃

肌肉萎縮症:開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7146IDB

Summary

Global Markets Direct's, 'Muscle Atrophy - Pipeline Review, H2 2015', provides an overview of the Muscle Atrophy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Muscle Atrophy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Muscle Atrophy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscle Atrophy Overview
  • Therapeutics Development
    • Pipeline Products for Muscle Atrophy - Overview
    • Pipeline Products for Muscle Atrophy - Comparative Analysis
  • Muscle Atrophy - Therapeutics under Development by Companies
  • Muscle Atrophy - Therapeutics under Investigation by Universities/Institutes
  • Muscle Atrophy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Muscle Atrophy - Products under Development by Companies
  • Muscle Atrophy - Products under Investigation by Universities/Institutes
  • Muscle Atrophy - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Biogen, Inc.
    • Eli Lilly and Company
    • Fate Therapeutics, Inc.
    • Rigel Pharmaceuticals, Inc.
  • Muscle Atrophy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACE-083 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIIB-023 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • landogrozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Growth and Differentiation Factor 8 for Ventilator Atrophy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Muscle Atrophy - Recent Pipeline Updates
  • Muscle Atrophy - Dormant Projects
  • Muscle Atrophy - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Muscle Atrophy, H2 2015
  • Number of Products under Development for Muscle Atrophy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Muscle Atrophy - Pipeline by Acceleron Pharma, Inc., H2 2015
  • Muscle Atrophy - Pipeline by Biogen, Inc., H2 2015
  • Muscle Atrophy - Pipeline by Eli Lilly and Company, H2 2015
  • Muscle Atrophy - Pipeline by Fate Therapeutics, Inc., H2 2015
  • Muscle Atrophy - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Muscle Atrophy Therapeutics - Recent Pipeline Updates, H2 2015
  • Muscle Atrophy - Dormant Projects, H2 2015
  • Muscle Atrophy - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Muscle Atrophy, H2 2015
  • Number of Products under Development for Muscle Atrophy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top